Food based phytochemical luteolin their derivatives, sources and medicinal benefits


1Institute of Home and Food Sciences, Faculty of Sciences and Technology, Government College University Faisalabad, Pakistan

2Department of Chemistry, Faculty of Sciences and Technology, Government College University Faisalabad, Pakistan

*Author to whom correspondence should be addressed/E-Mail:

Received: June 2017 / Accepted:  June 2017/ Published: June 2017

ABSTRACT: Luteolin is a type of flavonoid and a 3′, 4′, 5, 7-tetra hydroxyl flavone with a yellow crystalline appearance. Luteolin is widely present in different plant families such as, Lamiacea, Arecaceae, Brassicaceae, Campanulaceae, Asteraceae, Resedaceae and Scrophulariaceae. Luteolin mostly found in edible plants and most important food based phytochemical. Dietary sources of luteolin such as, celery, peppers, carrots, peppermint, olive oil, thyme, oregano and rosemary, etc. On the base of luteolin content among other sources oregano is the better source with 1028.75mg/100g contents. Flavonoids are important component of plants, and widely used in traditional medicine to cure the different type of diseases. Luteolin has different health benefits such as, anti-inflammatory, sun protectant, anti-oxidant, improve heart function, neurological impairments, anti-cancer and many more. Luteolin has many possible mechanisms involved in different biological activities such as, stabilization of p53, modulation of ROS levels, and reduction of NF-kappaB, reduction of AP-1 activity and inhibition of PI3K.

Keywords: Luteolin, Flavonoid, Derivatives, Source, Health benefits.



Luteolin is belonging to the class of flavonoids and yellow crystalline compound of Flavones. Luteolin widely found in plant kingdom, especially in edible plants. It is a 3′, 4′, 5, 7-tetra hydroxyl flavone. Flavonoids play significant role against insects, microorganisms and UV irradiation to defending the plant cells because they are polyphenols in nature (Harborne and Williams, 2000). Flavonoids for animal and human health are beneficial, it is clear and suggested from the previous studies of animal, cell culture, and human population. Flavonoids are common nutrients play an important role as an estrogenic regulators, antioxidants, and antimicrobial agents, because these are present in better amount in foods, such as in fruits, vegetables and medicinal herbs (Birt et al., 2001). Flavonoids are also act as a cancer preventive, it has been noticed from previous study (Knekt et al., 1997; Neuhouser, 2004). During the progression of carcinogenesis flavonoids may block many points, including cell transformation, metastasis, angiogenesis and invasion due to the inhibition of kinases. Flavonoids regulating cell cycle, reducing the transcription factors and also induced apoptotic cell death (Birt et al., 2001).


1.1. Chemical structure of luteolin

Luteolin is flavonoids belonging to the flavone, its structure consist of C6-C3-Cand also possess two benzene rings. In structure of luteolin third is oxygen containing carbon ring and double bond is present at 2-3 carbon. Luteolin structure also consist of hydroxyl groups at different carbons positions as shown in Figure 1 (Ross and Kasum, 2002). Biological and biochemical activities of luteolin are associated with hydroxyl moieties and the position of 2-3 double bonds present in structure (Chan et al., 2003; Hempel et al., 1999). Some part of luteolin, when passing through intestinal mucosa converted into glucuronides (Shimoi et al., 1998).  Luteolin shows better heat stability during cooking, that’s why losses of luteolin relatively low (Le-Marchand, 2002).


1.2. Derivate of luteolin

Luteolin is a flavonoid mostly found in plant kingdom. Luteolin mostly found in herbs such as, Lonicera japonica, Nepeta cateria L, Chrysanthemum morifolium and Ajuga decumbens Thunb. Some previous findings are evident of medicinal benefits, which possesses by luteolin such as anticancer, natural sun protectant, improve heart function, anti- inflammation and antioxidant. According to some previous evident luteolin and some of their important derivatives such as, Luteolin 4′-neohesperidoside, 7-glucuronide-3′-glucoside, 7-sambubioside, 7-galacturonide-4′-glucoside, 7-O-rutinosides, 7, 3′-diglucuronide, 7-gentiobioside, 7-O-glucoside, and many more present in Table 1 with their plant source and their possible structures (Lin et al., 2008).



3. Source of Luteolin

Luteolin is a significant phytochemical and most commonly found in bunch of vegetables. Fruits and vegetables such as parsley, thyme, celery, olive oil, onion leaves, broccoli, peppermint, peppers, rosemary, oregano, cabbages, carrots, artichoke, chrysanthemum flowers and apple skins are rich source of luteolin (Miean and Mohamed, 2001; Mencherini et al., 2007). According to Table 2 the richest source of luteolin in case of vegetables radicchio and raw Chinese celery in which luteolin is 37.96mg and 34.87mg respectively. In case of herbs most prominent source of luteolin is oregano (1028.75mg) and then juniper berries with 69.05mg. In known plant source, luteolin present in better quantity in fresh sage (16.70mg). In case of fruits, raw lemon without peel contain (1.50mg) better amount of luteolin content. Overall, in case of vegetables, fruits, herbs and plants oregano is best source of luteolin content.


4. Health benefits of luteolin

4.1. Luteolin Fights Cancer

Luteolin is constituent of our daily nutrition but their amount is relatively less than 1mg/day. Inverse correlation is suggested by some epidemiological studies between the risk of some cancer types and luteolin intake (Seelinger et al., 2008). The cancer cells growth block or delayed in vivo and in vitro due to the intake of luteolin in daily nutrition, by tumor cell proliferation inhibition, protection of carcinogenic stimuli, apoptosis induction through the intrinsic signaling and extrinsic signaling pathways and due to the induction cell cycle arrest. When compare the luteolin with other flavonoids, luteolin is most effective one among all of these for the inhibition of tumor cell proliferation. Proliferation of different type of tumor cell effectively subdued with luteolin in vitro about 3 to 50 µM with IC50. Tumor growth effectively inhibited in vivo with the concentration of luteolin 50 molecule to 200ppm in food (Selvendiran et al., 2006) and in application of intragastric 5 to 10 mg/kg (Fang et al., 2007) or 0.1 -0.3 mg/kg/d (Manju et al., 2007). In human skin, luteolin having ability to penetrate and effectively capable for the treatment and prevention of skin cancer (Seelinger et al., 2008). Various types of cancer cells development restricted by luteolin. It inhibits the carcinogens metabolism, inhibit new blood vessels growth inside tumors, stopping the progression of cancer cell cycle and also induced the cell death in cancer cells (Pitot, 1993). Some studies in case of mice are evident, growth of tumor formed due to human skin hepatoma, carcinoma and human ovarian cancer cell effectively restricted by the use of luteolin. Luteolin significantly inhibits the occurrence rate and also reduce the tumors size. Use of luteolin is safe as an anti-cancer agent because their long term treatment at a dose of 30mg/kg in rats did not show any visible toxicity (Hanahan, 2000). Against cancer preventive and therapeutic activities associated with estrogen was found in luteolin through vivo and vitro experiments (Galati et al., 2000).


Luteolin has a chemo-preventive effect on skin cancer induced by ultra violet (UV). Ultraviolet B induced protein-1 activator, cyclooxygenase-2 expression and activity of nuclear factor kappa B (NF-κB) in JB6 P+ cells suppressed by luteolin. Kinase and immunoblot assay data from some studies indicate that luteolin reduce the effect of Src kinase activities, and epsilon (protein kinase CƐ (PK CƐ)). Afterward, luteolin inhibit the Akt signaling pathway and phosphorylation of MAPK (mitogen-activated protein kinases) induced by ultraviolet B (Byun et al., 2010). Pull-down assays described that in an ATP-competitive manner luteolin directly binds to the protein kinase CƐ (PK CƐ) and Src.  In SKH-1 hairless mice, luteolin suppressed the occurrence of tumor, multiplicity of tumor and their overall size. Some previous evident shows that the skin analysis through immunoblotting and immunohistochemistry indicate that the luteolin cause reduction tumor necrosis factor α (TNFα), cyclooxygenase-2 and proliferating cell nuclear antigen. Luteolin inhibit Src kinase and protein kinase CƐ (epsilon) activity. Luteolin cause vigorous chemopreventive activity against skin cancer induced by ultraviolet B by targeting the Src and protein kinase CƐ (epsilon) (Byun et al.,2010).


4.2. Luteolin reduce Inflammation

Inflammation that protect over body against heal injury and infection because it is a body defensive mechanism. Results of chronic inflammation some harmful diseases such as arthritis, cancer and arthritis obstructive pulmonary disease (Brody and Spira, 2006; Perwez and Harris, 2007; Karin et al., 2006). Activation of microphages during inflammation by different molecules, such as cytokines and toxins from the host and pathogens respectively. Gram-negative bacteria outer membrane components are Lipopolysaccharide (LPS).  Lipopolysaccharide is a common trigger for inflammation and endotoxin. Microphages after their activation produce inflammatory molecule vigorously, such as interleukins (ILs), free radicals and tumor necrosis factor α (TNFα). These are leading toward the recruitment of inflammatory cells, in which lymphocytes and neutrophils for the clearance of pathogens and infection site (Brody and Spira, 2006; Karin et al., 2006).  During chronic inflammation continuous production of these molecule may cause cancer like diseases. Luteolin retard the development of these type of cytokines. It is also retard their transduction signal pathways by exerting its anti-inflammatory effects (Xagorari et al., 2001; Chen et al.,2004; Kumazawa et al., 2006). In vivo luteolin suppress the bacteria induced or lipopolysaccharide inflammation in vivo, evident from animals study (Kotanidou et al., 2002; Tormakangas et al., 2005). Luteolin effectively alleviated the high molarity induced by lipopolysaccharide. These lipopolysaccharides release in intercellular adhesion molecule-1 (ICAM-1) and serum expression in the liver and associated with the reduction of lipopolysaccharides stimulated tumor necrosis factor α (TNFα) (Kotanidou et al., 2002). Inflammation caused by Chlamydia pneumoniae in lungs tissue has been suppressed with the use to luteolin (Tormakangas et al., 2005). Many direct evidence in vitro studies for the anti-inflammatory effect of luteolin’s. Release of interleukins-6 (IL-6) and inhibited lipopolysaccharides stimulated tumor necrosis factor α (TNFα) with luteolin and pretreating murine microphage. These are associated with the blockage of MAPK (mitogen-activated protein kinase) family member (JNK, ERK and p38) and activation of NF-κB (nuclear factor kappa B) produced by lipopolysaccharide (Chen et al., 2007; Xagorari et al., 2002).


Two important pathways that include in the activation of MAPK and NF-κB, in responses of stromal cells and epithelial tissue to inflammation mediators (ILs and TNFα) (Karin, 2004). These pathways suppressed due to the use of luteolin underlines the basic mechanism of its inhibitory action on chronic and acute inflammation. On the level of receptor, suppression of inflammatory is partly due to the lipid rafts accumulation. Cytokine induced signaling was blocked with the help of luteolin because it is a crucial point for receptor signaling (Kumazawa et al., 2006). Primary inflammatory stimulators lipopolysaccharides (LPS) and secondary tumor necrosis factor α (TNFα) and interleukins-1 (IL-1) activated the NF-κB. The NF-κB and RelA (p65)/p50 are constituent of heterodimer. These are retained as an inactivated form in cytoplasm due to the association of IκB proteins.


Lipopolysaccharides helpful for the activation of IKK (IκB kinase) due to the binding of TLR-4 (Toll-like receptor 4). Activation of IKK (IκB kinase) turns phosphorylates IκB to start the quick degradation and also permit NF-κB to move into the nucleus. In nucleus activated the targets, such as cytokines and anti-apoptotic properties (IL-1 and TNFα) (Hayden and Ghosh, 2004). Cytokine established the feedback loop for NF-κB by binding the cognate receptors. Inflammatory cytokines convert at IKK (IκB kinase) activation due to the activation of nuclear factor kappa B (NF-κB) pathways by Lipopolysaccharides (Hayden and Ghosh, 2004).

NF-κB pathways are effectively blocked by luteolin. Luteolin can also interferes with the function of primary and secondary inflammatory stimulators through IκB degradation and IKK activation (Chen et al., 2004). Luteolin blocks the upstream steps or directly inhibits IKK activity. Receptor signaling complex formation occur in the IKK activation pathway.  On the base of observations, strong antioxidant activities of some flavonoids are ineffective in restricted lipopolysaccharides stimulated tumor necrosis factor α (TNFα) production (Devasagayam et al., 1995). That’s why, the luteolin have ability to directly scavenge reactive oxygen species (ROS). Lipopolysaccharides activated nitric oxide production also suppressed by luteolin in activated macrophages (Hu and Kitts, 2004). Luteolin can also useful inhibit inflammation in the colon. Luteolin role as an anti-inflammation also take part as a cancer prevention (Kamata et al., 2005; Karin and Greten, 2005). In anti-inflammatory treatment, luteolin had great success as compare to prednisolone.


4.3. Luteolin as an antioxidant

Most of flavonoids are considered as an antioxidants including luteolin. Reactive oxygen species (ROS) belong to a multiple group of reactive, oxygen containing species such as, hydrogen peroxide (H2O2), singlet oxygen (1O2), hydroxyl radical (OH), superoxide (O2•−) and lipid peroxyl radical (LOO) and short lived. For cellular signaling ROS serve as second messengers (Nimnual et al., 2003). Excessive ROS (reactive oxygen species) production may cause the damage of DNA, protein, lipids and oxidative stress. These are involved is cancer as well as neurodegenerative and cardiovascular diseases. Reactive oxygen species induced Damage of DNA, lipids and protein induced by reactive oxygen species inhibit by luteolin (Robak et al., 1988).


First functions of luteolin as a scavenger of reactive oxygen species through its own oxidation (Lien et al., 1999). Luteolin structure contain 3′, 4′ hydroxylation, double bond at 2nd and 3rd carbons and carbonyl group at carbon number 4. This structure is essential to flavonoids for antioxidant activity (Lien et al., 1999). The hydrogen atom donate to free radicals from an aromatic hydroxyl group. Luteolin as an aromatic compound, around the M-electron system supported unpaired electron.  Some studies shows that, luteolin as a scavenger of reactive oxygen species was found in cell free system.


Secondly, luteolin also inhibits or retard the growth of ROS generating oxidase, such as inhibits the superoxide formation y suppressing the activity xanthine oxidase (Nagao et al., 1999). However, in mitochondria luteolin whether effects on ROS generation is unclear in mammalian cells. In leishmanial (parasite) cells it interferes with the electron transport chain of mitochondria (Sen et al., 2006).


Third function of luteolin as an antioxidant, luteolin influence by enhancing or protecting endogenous antioxidants such as superoxide dismutase (SOD), glutathione-S-transferase (GST), catalase (CAT) and glutathione reductase (GR) (Leung et al., 2006; Manju and Nalini, 2005).


Fourth function of luteolin as an enzymes inhibition, directly inhibit the enzymes activity that catalyze the oxidation of cellular component. Such as luteolin restrict the growth or formation of cyclooxygenase, lipoxygenase and acid-stimulated malonaldehyde in liver lipids (Robak et al., 1988).


Luteolin, last function to cause chelation of transition metal ions. Because due to these ions generation of ROS occur and also control the oxidation of non-transition metal-dependent or inhibit the reaction of lipooxygenase (Ross and Kasum, 2002). In vivo, it should be observed that the luteolin concordant antioxidant mechanism may occur. For example, luteolin inhibit the production of hydroxyl radicals (OH) in microphages induced by lipopolysaccharides, through scavenging superoxide (O2•−). Also inhibiting the activity of xanthine oxidase (Harris et al., 2006).


4.4. Luteolin is a natural sun protectant

In HaCaT cells, luteolin reduce the ultraviolet B induced (UVB) expression of matrix metalloproteinase (MMP-1) and may cause the direct inhibition or reduce the activity of p90RSK2 (Ribosomal S6 Kinase) and JNK1 (Jun N-terminal kinase). Due to the ultraviolet B (UVB) chronic irradiation in SKH-1 hairless mice, luteolin impaired the wrinkle formation. Intrinsic ageing and extrinsic ageing or photo-ageing are the two basic processes of skin ageing (Chung, 2003). Characterization of intrinsic ageing done by dry, smooth, pale and wrinkle skin. Characterization of photo-ageing by pigmentary changes, deep wrinkles and generally appearing when the face, forearm and neck are sun-exposed (Chung, 2003). Photo-ageing caused by UV radiation but UVB cause the major contribution.  In vivo, in human dermal epidermis and cultured epidermal keratinocytes, matrix metalloproteinase-1 (MMP-1) expression induced by UV and UVB (Tanaka et al., 2005). Interstitial collagenase matrix metalloproteinase-1 play an essential role for fibrillar collagens by cleaving. The role or function mainly performed to keep skin resilience and elasticity. After cleavage reactions by collagenases including MMP-1, triple-helical fragments (1/4 C-terminal and 3/4 N-terminal) are produced and spontaneously denature at room temperature in gelatin and further degraded into small peptide due to other matrix metalloproteinases (Ala-aho and Kahari, 2005). That’s why, the inhibition or prevention of matrix metalloproteinase-1 (MMP-1) overexpression encourage by ultraviolet B could indicate the novel approach to suppress or reduce the photo-ageing (Brennan et al., 2003). Some previous studies described that the naturally occurring compounds, such as luteolin exerts anti-photo ageing effect (Kim et al., 2009; Fisher et al., 1999).


AP-1 (Activator protein-1) produced by ultraviolet B, their activation was inhibited by luteolin. Activation of c-Jun (Jun protein), c-Fos (Fos Protein) and phosphorylation these are major components of AP-1 complex (Angel and Karin, 1991). Activation of c-Fos promoter and phosphorylation of c-Jun induced by UVB (ultraviolet-B). Effect of these are inhibited by the use of luteolin. Upstream kinases, such as JNK (Jun N-terminal kinase), Ribosomal S6 Kinase (RSK) and ESR (extracellular signal-regulated kinase) control the transcription factors c-Jun and c-Fos (Whitmarsh and Davis, 1996; Cesare et al., 1998). In contrast, ultraviolet-B (UVB) induced phosphorylation of ERK, JNK and RSK, which is not suppressed by luteolin treatment. Luteolin after phosphorylation directly inhibiting or suppressing their kinase activity. Results of kinase assay In vitro study, show that the significant effects of luteolin on the inhibition of p90RSK2 and JNK1 activity, but not effective against the activity of ERK2 and JNK2. Moreover, luteolin directly bound to JNK1 but not JNK2 in an ATP-competitive manner, indicated by pull-down assays. In an ATP-independent manner luteolin bound the RSK2. Evident form previous studies, clearly indicate that the wrinkle formation in SKH-1 hairless mice, induced by chronic UVB suppressed by luteolin treatment. MMP-13 expression induced by UVB, in a mouse skin lysates effect of rodent interstitial collagenase, significantly suppressed by the use of luteolin.


A well-known transcription factor AP-1, that activates the target genes and binds to the TRE with the consensus sequence TGACTCA (Angel and Karin, 1991; Rittie and Fisher, 2002). Complex of activator protein-1 consist of Fos and Jun family proteins that are regulated by mitogen-activated protein kinases (MAPKs) (Whitmarsh and Davis, 1996).


Phosphorylation of the c-Jun activation domain caused by Jun N-terminal kinase. Upstream kinase of c-Jun activates its transcription activity (Derijard et al., 1994). Expression of c-Fos and c-Jun genes correlates with the activity of AP-1 and is regulated by p38, ERK and p90RSK (Whitmarsh and Davis, 1996; Cesare et al., 1998). From some previous studies, Ultraviolet-B (UVB) irradiation found to induce the activation of c-Fos and phosphorylation of c-Jun, these are suppressed through direct inhibition of their upstream kinases p90RSK2 and JNK1 by the luteolin treatment.


MAPK (Mitogen-activated protein kinases) family members such as JNKs (c-Jun N-terminal kinases) are heavily involved in proliferation, apoptosis and cell survival (Bode and Dong, 2007). Different AP-1 components such as, JunD, c-Jun and activating transcription factor 2 (ATF2) phosphorylated by JNKs. The c-Jun N-terminal kinases can also phosphorylate the c-Myc, Elk1, MLK2, p53, histone H3 and tau (Bode and Dong, 2007). In different cases reported that the c-Jun phosphorylated only by JNKs (Gupta et al., 1996). In phosphorylation of c-Jun the role of JNKs remains controversial. The role of JNK2 as a negative regulator of c-Jun reported by Sabapathy and Wagner (2004). On the other hand, role of JNK2 as a positive regulator of c-Jun reported by Jaeschke et al., (2006). However, an agreement done about the JNK1, positive regulator of c-Jun (Sabapathy and Wagner, 2004; Jaeschke et al., 2006). Luteolin have a potential to inhibit the wrinkle formation and matrix metalloproteinase (MMP-1) expression induced by ultraviolet-B in vitro and in vivo. For the inhibition of signal transduction induced by ultraviolet-B, leading to matrix metalloproteinase (MMP-1) up-regulation, p90RSK2 and JNK1 for luteolin are novel molecular targets and a very useful agent for the prevention of skin ageing induced by UVB.


4.5. Luteolin improve heart function

In the biological system, luteolin is known as a free radical scavenger or an antioxidant (Horvathova et al., 2005; Huang et al., 2005). Cardiomyocytes, antioxidant power following Simulated Ischemia/Reperfusion (SI/R) enhanced by luteolin, due to the decrease in subsequent production of malondialdehyde (MDA), lipid peroxidation, production of ROS and increase in the activity of superoxide dismutase (SOD). In pathophysiology ROS play functional role against the myocardial SI/R injury (Tsutsui et al., 2008; Liao et al., 2011). Some earlier studies propose that, the antioxidant activity of luteolin during myocardial SI/R overcome the mass production of free radicals derived from oxygen (Miura and Miki, 2009). The essential proteins and cell membrane lipids interaction with the free radicals derived from oxygen, lead toward the electro-physiologic, metabolic and functional changes of the myocardium. These changes may also induced the potentially myocardial necrosis and lethal ventricular arrhythmia (Hausenloy et al., 2005).


Several previous studies described that the SI/R-induced oxidative damage of cardiomyocytes reduce or suppressed by luteolin. Luteolin shows the protective action to rescue the rat heart tissue against the ischemia/ reperfusion injury (I/R) by suppressing the expression of inducible nitric oxide synthase (Liao et al., 2011). Also the production of nitric oxide reduce, which may prevent from the interaction of superoxide radical with nitric oxide, by that means protect free radical injury. In vitro some previous evident indicate that the luteolin effectively protect the myocardium from oxidative injury induced by SI/R.


In cardiomyocytes the NOX2 protein increase, followed by I/R injury. Pretreatment under these conditions with luteolin restrict the NOX2 protein expression and the same results also found for mRNA expression. NOX2 mRNA expression down-regulated by luteolin. According to the analysis of western blot, luteolin through transcription effects the NOX2 expression, which correlates with the change of its protein levels seen in injury in cardiomyocytes induced by SI/R.


Reactive oxygen species (ROS) are better known for the inactivation of anti-oxidative proteases. In the cell, a set of effective anti-oxidative enzymes play an important role as a defense mechanism to secure the organisms  from damage induced by reactive oxygen species (ROS). These enzymes such as, SOD, catalase (CAT) and glutathione peroxidase (GSH2Px) and among others. These enzymes suppressing the free radical reaction by causing chemical changes in ROS. Anti-oxidative proteases could be inactivate the explosive increase in reactive oxygen species following SI/R, resulting in protein denaturation, DNA damage and lipid peroxidation. During redox reaction, in the intracellular space reactive oxygen species can also cause changes in the conformation of the macromolecules and structure, because of that in cellular apoptosis regulating the signal transduction. To protect the cardiomyocytes from SI/R induced oxidative damage, luteolin effectively scavenge the reactive oxygen species.  In myocardial hypertrophy molecular mechanism, the ROS play an important role or participating for the activation of p38MAPK.


In myocardial protection, the activation of PI3K/Akt pathway play a significant role (Hausenloy et al., 2005). Pretreatment with luteolin may involve the PI3K/Akt survival pathway. The expression level of phosphorylated Akt increased by pretreatment with luteolin and PI3K inhibitor (LY294002) partially inhibit this increase. Phosphorylated Akt could be activate the NOX2 expression and this effect is eliminate to a considerable degree by the PI3K inhibitor (LY294002). Luteolin provide protection to cardiomyocytes by activating the PI3K/Akt signaling pathway, inhibiting oxidative stress and improving cardiomyocyte contractile function from SI/R-induced injury. Phosphorylation of p38MAPK and expression of NOX2 significantly reduced by pretreatment with luteolin, on the other hand luteolin exert cardio-protective effect by enhancing the phosphorylation of Akt.



Luteolin widely present in the plant kingdom, mostly in edible plants. Overall the best source of luteolin is oregano with 1028.75mg/100g and followed by Juniper Berries with 69.05mg/100g. Flavonoids are important component of plants, and widely used in traditional medicine to cure the different type of diseases. In some studies on animal luteolin exerts its biological properties in vivo. Luteolin has different health benefits such as, anti-inflammatory, sun protectant, anti-oxidant, improve heart function, neurological impairments, anti-cancer and many more.



1.        Harborne JB, Williams CA, 2000. Advances in flavonoid research since 1992. Phytochemistry, 55: 481–504.

2.        Birt DF, Hendrich S, Wang W, 2001. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol. Ther., 90: 157–177.

3.        Knekt P, Jarvinen R, Seppanen R, Hellovaara M, Teppo L, Pukkala E, Aromaa A, 1997. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am. J. Epidemiol., 146: 223–230.

4.        Neuhouser ML, 2004. Dietary flavonoids and cancer risk: evidence from human population studies. Nutr. Cancer, 50: 1–7.

5.        Ross JA, Kasum CM, 2002. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr., 22: 19–34.

6.        Chan TS, Galati G, Pannala AS, Rice-Evans C, O’Brien PJ, 2003. Simultaneous detection of the antioxidant and pro-oxidant activity of dietary polyphenolics in a peroxidase system. Free Radic. Res., 37: 787–794.

7.        Hempel J, Pforte H, Raab B, Engst W, Bohm H, Jacobasch G, 1999. Flavonols and flavones of parsley cell suspension culture change the antioxidative capacity of plasma in rats. Nahrung, 999; 43: 201–204.

8.        Shimoi K, Okada H, Furugori M, Goda T, Takase S, Suzuki M, Hara Y, Yamamoto H, Kinae N, 1998. Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett., 438: 220–224.

9.        Le-Marchand L, 2002. Cancer preventive effects of flavonoids–a review. Biomed. Pharmacother., 56: 296–301.

10.     Li YL, Li Y, Wang NL, Yao XS, 2008. Flavonoids and a New Polyacetylene from Bidens parviflora Willd. Molecules, 13; 1931-1941.

11.     Harborne BJ, Baxter H, 1999. The Handbook of Natural Flavonoids. John Wiley & Son.

12.     Elbandy M, Elbandy M, Miyamoto T, Dubois MAL, 2007. Sulfated Lupane Triterpene Derivatives and a Flavone C-Glycoside from Gypsophila Repens. Chem. Pharm. Bull., 55; 808-811.

13.     Materska M, Piacente S, Stochmal A, Pizza C, Oleszek W, Perucka I, 2003. Isolation and structure elucidation of flavonoid and phenolic acid glycosides from pericarp of hot pepper fruit Capsicum annuum L. Phytochemistry, 63; 893-8.

14.     Xie H, Wang T, Matsuda H, Morikawa T, Yoshikawa M, Tanib T, 2005. Bioactive Constituents from Chinese Natural Medicines. Inhibitory Effect on Aldose Reductase and Structures of Saussureosides A and B from Saussurea medusa Chem. Pharm. Bull., 3; 1416—1422.

15.     Chan K, 2005. Chinese medicinal materials and their interface with Western medical concepts. J. Ethnopharmacol., 6; 1–18.

16.     Hayashi T, Sawa K, Kawasaki M, Arisawa M, Shimizu M, Morita N, 1988. Inhibition of cow’s milk xanthine oxidase by flavonoids. J. Nat. Prod., 51: 345–348.

17.     Lu Y, Foo LY, 2002. Polyphenolics of Salvia–a review. Phytochemistry, 59(2); 117-40.

18.     Markham KR, 1988. The major flavonoids of an antarctic Bryum. Phytochemistry, 27(9); 2843-2845.

19.     Mues R, 1983. Specie specific flavone glucuronidase in elodea species. Biochemis. Syst. Ecol., 11; 261-261.

20.     Mitchell KA, Markham KR, Bayly MJ, 2001. Flavonoid characters contributing to the taxonomic revision of the Hebe parviflora complex. Phytochemistry, 56(5); 453-61.

21.     Mansour RMA, Ahmed AA, Saleh NAM, 1983. Flavone glycosides of some Launaea species. Phytochemistry, 22 (11); 2630-2631.

22.     Abdalla MF, Saleh NAM, Gabr S, Abu-Eyta AM, El-Said H, 1983. Flavone glycosides of Salvia triloba. Phytochemistry, 22(9); 2057-2060.

23.     Markham KR, Porter IJ, 1974. Flavonoids of the liverwort Marchantia polymorpha. Phytochemistry, 13(9); 1937-1942.

24.     Markham KR, Porter LJ, 1975. Isoscutellarein and hypolaetin 8-glucuronides from the liverwort Marchantia berteroana. Phytochemistry, 14(4); 1093-1097.

25.     EI-Negoumy SI, Mansour RMA, 1989. Grasas Aceites (Seville). 40; 87.

26.     Brown NE, Ghazala H, Rizwani K, Ghani U, Ahmad VU, 1990. Flavone Glycosides of Caralluma tuberculata. Pak. J. Pharm Sci., 3(2); 27.

27.     Williams CA, 1979. The leaf flavonoids of the orchidaceae. Phytochemistry, 18(5); 803-813.

28.     Miean KH, Mohamed S, 2001. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J. Agric. Food Chem., 49; 3106–3112.

29.     Mencherini T, Picerno P, Scesa C, Aquino R, 2007. Triterpene, Antioxidant, and Antimicrobial Compounds from Melissa officinalis. J. Nat. Prod., 70; 1889–1894.

30.     Seelinger G, Merfort I, Wolfle U, Schempp CM, 2008. Anti-carcinogenic effects of the flavonoid luteolin. , 13(10); 2628-51.

31.     Lin Y, Shi R, Wang X,  Shen HM, 2008. Luteolin, a flavonoid with potentials for cancer prevention and therapy. Curr. Cancer Drug Targets, 8(7); 634–646.

32.     Pitot HC, 1993. Multistage carcinogenesis–genetic and epigenetic mechanisms in relation to cancer prevention. Cancer Detect. Prev., 17; 567–573.

33.     Hanahan D, Weinberg RA, 2000. The hallmarks of cancer. Cell, 100; 57–70.

34.     Galati G, Teng S, Moridani MY, Chan TS, O’Brien PJ, 2000. Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug. Metabol. Drug. Interact., 17; 311–349.

35.     Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, Torimura T, Yano H, Kojiro M,  Sata M, 2006. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatomacells: an implication for the antitumor potential of flavonoids. Cancer Res. 66; 4826-4834.

36.     Fang J, Zhou Q, Shi XL, Jiang BH, 2007. Luteolininhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis, 28; 713-723.

37.     Manju V, Nalini N, 2007. Protective role of luteolin in 1, 2-dimethylhydrazineinduced experimental colon carcinogenesis. Cell Biochem. Funct., 25; 189-194.

38.     Byun S, Lee KW, Jung SK, Lee EJ, Hwang MK, Lim SH, Bode AM, Lee HJ, Dong Z, 2010. Luteolin inhibits protein kinase C (epsilon) and c-Src activities and UVB-induced skin cancer. Cancer Res., 70(6); 2415-23.

39.     Brody JS, Spira A, 2006. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc. Am. Thorac. Soc., 3; 535–537.

40.     Perwez HS, Harris CC, 2007. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer, 121; 2373–2380.

41.     Karin M, Lawrence T, Nizet V, 2006. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell, 124; 823–835.

42.     Xagorari A, Papapetropoulos A, Mauromatis A, Economou M, Fotsis T, Roussos C, 2001. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J. Pharmacol. Exp. Ther., 296; 181–187.

43.     Chen CC, Chow MP, Huang WC, Lin YC, Chang YJ, 2004. Flavonoids Inhibit Tumor Necrosis Factor-{alpha}-Induced Up-Regulation of Intercellular Adhesion Molecule-1 (ICAM-1) in Respiratory Epithelial Cells through Activator Protein-1 and Nuclear Factor-{kappa} B: Structure-Activity Relationships. Mol. Pharmacol., 66;683–693.

44.     Kumazawa Y, Kawaguchi K, Takimoto H, 2006. Immunomodulating effects of flavonoids on acute and chronic inflammatory responses caused by tumor necrosis factor alpha. Curr. Pharm. Des., 12;4271–4279.

45.     Kotanidou A, Xagorari A, Bagli E, Kitsanta P, Fotsis T, Papapetropoulos A, Roussos C, 2002. Luteolin Reduces Lipopolysaccharide-induced Lethal Toxicity and Expression of Proinflammatory Molecules in Mice. Am. J. Respir. Crit. Care Med., 165;818–823.

46.     Tormakangas L, Vuorela P, Saario E, Leinonen M, Saikku P, Vuorela H, 2005. In vivo treatment of acute Chlamydia pneumoniae infection with the flavonoids quercetin and luteolin and an alkyl gallate, octyl gallate, in a mouse model. Biochem. Pharmacol., 70;1222–1230.

47.     Chen CY, Peng WH, Tsai KD, Hsu SL, 2007. Luteolin suppresses inflammation-associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophages. Life Sci., 81;1602–1614.

48.     Xagorari A, Roussos C, Papapetropoulos A, 2002. Inhibition of LPS-stimulated pathways in macrophages by the flavonoid luteolin. Br. J. Pharmacol., 136;1058–1064.

49.     Karin M, 2004. Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs. Ann. Rheum. Dis., 63(Suppl 2):ii62–ii64.

50.     Hayden MS, Ghosh S, 2004. Signaling to NF-kappa B. Genes Dev., 18:2195–2224.

51.     Chen CC, Chow MP, Huang WC, Lin YC, Chang YJ, 2004. Flavonoids inhibit tumor necrosis factor-alpha-induced up-regulation of intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells through activator protein-1 and nuclear factor-kappa B: structure-activity relationships. Mol. Pharmacol., 66;683–693.

52.     Devasagayam TP, Subramanian M, Singh BB, Ramanathan R, Das NP, 1995. Protection of plasmid pBR322 DNA by flavonoids against single-stranded breaks induced by singlet molecular oxygen. J. Photochem. Photobiol. B., 30;97–103.

53.     Hu C, Kitts DD, 2004. Luteolin and luteolin-7-O-glucoside from dandelion flower suppress iNOS and COX-2 in RAW264.7 cells. Mol. Cell. Biochem., 265;107–113.

54.     Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M, 2005. Reactive oxygen species promote TNF alpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell, 120;649–661.

55.     Karin M, Greten FR, 2005. NF-kappa B: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol., 5;749–759.

56.     Ross JA, Kasum CM, 2002. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr., 19–34.

57.     Nimnual AS, Taylor LJ, Bar-Sagi D, 2003. Redox-dependent down regulation of Rho by Rac. Nat. Cell. Biol., 5;236–241.

58.     Robak J, Shridi F, Wolbis M, Krolikowska M, 1988. Screening of the influence of flavonoids on lipoxygenase and cyclooxygenase activity, as well as on nonenzymic lipid oxidation. Pol. J. Pharmacol. Pharm., 40;451–458.

59.     Lien EJ, Ren S, Bui HH, Wang R, 1999. Quantitative structure-activity relationship analysis of phenolic antioxidants. Free Radic. Biol. Med., 26;285–294.

60.     Nagao A, Seki M, Kobayashi H, 1999.  Inhibition of xanthine oxidase by flavonoids. Biosci. Biotechnol. Biochem., 63;1787–1790.

61.     Sen N, Das BB, Ganguly A, Banerjee B, Sen T, Majumder HK, 2006. Leishmania donovani: intracellular ATP level regulates apoptosis-like death in luteolin induced dyskinetoplastid cells. Exp. Parasitol., 114;204–214.

62.     Leung HW, Kuo CL, Yang WH, Lin CH, Lee HZ, 2006. Antioxidant enzymes activity involvement in luteolin-induced human lung squamous carcinoma CH27 cell apoptosis. Eur. J. Pharmacol., 534;12–18.

63.     Manju V, Nalini N, 2005. Chemopreventive potential of luteolin during colon carcinogenesis induced by 1,2-dimethylhydrazine. Ital. J. Biochem., 54;268–275.

64.     Harris GK, Qian Y, Leonard SS, Sbarra DC, Shi X, 2006. Luteolin and chrysin differentially inhibit cyclooxygenase-2 expression and scavenge reactive oxygen species but similarly inhibit prostaglandin-E2 formation in RAW 264.7 cells. J. Nutr., 136;1517–1521.

65.     Chung JH, 2003. Photoaging in Asians. Photodermatol. Photoimmunol. Photomed., 19;109 -21.

66.     Tanaka K, Hasegawa J, Asamitsu K, 2005. Prevention of the ultraviolet B-mediated skin photoaging by a nuclear factor kappaB inhibitor, parthenolide. J. Pharmacol. Exp. Ther., 315;624–30.

67.     Ala-aho R, Kahari VM, 2005. Collagenases in cancer. Biochimie., 87;273–86.

68.     Brennan M, Bhatti H, Nerusu KC, 2003. Matrix metalloproteinase-1 is the major collagenolytic enzyme responsible for collagen damage in UV-irradiated human skin. Photochem. Photobiol., 78; 43–8.

69.     Kim YG, Sumiyoshi M, Sakanaka M, 2009. Effects of ginseng saponins isolated from red ginseng on ultraviolet B-induced skin aging in hairless mice. Eur. J. Pharmacol., 602;148–56.

70.     Fisher GJ, Talwar HS, Lin J, 1999. Molecular mechanisms of photo aging in human skin in vivo and their prevention by all-trans retinoic acid. Photochem. Photobiol., 69;154–7.

71.     Angel P, Karin M, 1991. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta., 1072;129–57.

72.     Rittie L, Fisher GJ, 2002. UV-light-induced signal cascades and skin aging. Ageing Res. Rev., 1;705–20.

73.     Whitmarsh AJ, Davis RJ, 1996. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med., 74;589–607.

74.     Cesare DD, Jacquot S, Hanauer A, 1998. Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene. Proc. Natl. Acad. Sci. USA, 95;12202–7.

75.     Derijard B, Hibi M, Wu IH, 1994. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell, 76;1025–37.

76.     Bode AM, Dong Z, 2007. The functional contrariety of JNK. Mol. Carcinog., 46;591–8.

77.     Gupta S, Barrett T, Whitmarsh AJ, 1996. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J., 15;2760–70.

78.     Sabapathy K, Wagner EF, 2004. JNK2: a negative regulator of cellular proliferation. Cell Cycle, 3;1520–3.

79.     Jaeschke A, Karasarides M, Ventura JJ, 2006. JNK2 is a positive regulator of the cJun transcription factor. Mol. Cell, 23;899–911.

80.     Horvathova K, Chalupa I, Sebova L, Tothova D, Vachalkova A, 2005. Protective effect of quercetin and luteolin in human melanomaHMB-2 cells. Mutat. Res., 565;105-112.

81.     Huang SS, Liu SM, Lin SM, Liao PH, Lin RH, Chen YC, 2005. Antiarrhythmic effect of caffeic acid phenethyl ester (CAPE) on myocardial ischemia/reperfusion injury in rats. Clin. Biochem., 38;943 947.

82.     Tsutsui H, Kinugawa S, Matsushima S, 2008. Oxidative stress and mitochondrial DNA damage in heart failure. Circ. J., 72;A31-A37.

83.     Liao PH, Hung LM, Chen YH, Kuan YH, Zhang FB, Lin RH, 2011. Cardioprotective effects of luteolin during ischemiareperfusion injury in rats. Circ. J., 75;443-450.

84.     Miura T, Miki T, 2009. GSK-3β, a therapeutic target for cardiomyocyte protection. Circ. J., 73;1184-1192.

85.     Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM, 2005. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am. J. Physiol., 288;H971-H976.


Table 1. Derivatives of luteolin their plant source and structures

Derivatives Plant class Plant family Species Structure Refrences
Luteolin 7-arabinofuranosyl-(1->6)-glucoside Spermatophyta Podocarpaceae Dacrydium spp. (Harborne and Baxter, 1999)
Luteolin 7-arabinopyranosyl-(1->6)-glucoside Spermatophyta, Eudicotyledons Podocarpaceae, Caryophyllaceae Gypsophila repens, Dacrydium spp. (Elbandy et al., 2007; Harborne and Baxter, 1999)
Luteolin 7-sambubioside Asterids Lamiaceae Thymus membrane-ceus (Harborne and Baxter, 1999)
Luteolin 7-apiosyl-(1->2)-glucoside Asterids Apiaceae, Solanaceae

Apium graveolens, Petroselinum

 crism, Capsicum annuum (Harborne and Baxter, 1999; Materska et al., 2003)
Luteolin 7-O-rutinoside,
Luteolin 7-rutinoside
Asterids, Rosids, Liliopsida Lamiacea, Arecaceae, Brassicaceae, Campanulaceae, Asteraceae Saussurea medusa, Pratia nummularia, Capsella bursa-pastoris, Mentha aquatica L., Phoenix roebelenii (Harborne and Baxter, 1999; Lu and Foo, 2002; Xie et al., 2005)
 Lonicerin / Luteolin 7-neohesperidoside Asterids, Euphyllophyta Poaceae, Asteraceae, Plantaginaceae, Rutaceae Cymbopogon citraee, Chrysanthemum mo-rifolium, Saussurea medusa, Veronicastrum sibir-icum, Citrus aurantium (Chan, 2005; Harborne and Baxter, 1999; Hayashi et al., 1988)
Luteolin 7-gentiobioside Asterids Campanulaceae or Lobeliaceae Campanula rotundif-olia (Harborne and Baxter, 1999)
Luteolin 7-laminaribioside Liliopsida Colchicaceae Colchicum speciosum (Harborne and  Baxter, 1999; Markham, 1988)
Luteolin 7-allosyl-(1->2)-glucoside Asterids Labiatae Sideritis maura (Harborne and Baxter, 1999; Markham, 1988)
Luteolin 7-glucuronosyl-(1->2)-glucuronide Liliopsida Hydrocharitaceae Elodea canadensis (Harborne and Baxter, 1999; Mues, 1983)
Luteolin 7-glucoside-3′-xyloside Spermatophyta Podocarpaceae PodocarpusNivalis (Harborne and Baxter, 1999)
Luteolin 3′,7-di-O-beta-glucoside or
Luteolin 7,3′-diglucoside
Asterids, Rosids Asteraceae, Resedaceae, Scrophulariaceae Launaea nudicaulis, Reseda luteola, Hebe parviflora (Harborne and Baxter, 1999; Mitchell et al., 2001; Mansour et al., 1983)
Luteolin 7-glucuronide-3′-glucoside Asterids, Embryophyta Labiatae, Ricciaceae Salvia triloba, Riccia fluitans (Harborne and Baxter, 1999; Abdalla et al., 1983)
Luteolin 7,3′-diglucuronide Embryophyta Marchantiaceae Marchantia polymorpha (Harborne and Baxter, 1999; Markham and Porter, 1974)
Luteolin 7,3′-digalacturonide Embryophyta Marchantiaceae Marchantia berteroana (Markham and Porter, 1975)
 Luteolin 7,4′-diglucoside Asterids, Embryophyta, Rosids Asteraceae, Fabaceae, Jubulaceae Launaea nudicaulis, Vicia balansae, Frullania dilatata (Harborne and Baxter, 1999; Mansour et al., 1983)
Luteolin 7-galactoside-4′-glucoside Asterids Asteraceae Vernonia baldwinii, Vernonia greggii, Vernonia texana (Harborne and Baxter, 1999)
Luteolin 7-glucuronide-4′-rhamnoside Embryophyta Conocephalaceae Conocephalum Coicum (Harborne and Baxter, 1999)
Luteolin 7-galacturonide-4′-glucoside Asterids Apiaceae Cuminum cyminum (Harborne and Baxter, 1999; EI-Negoumy and Mansour, 1989)
Luteolin 7,4′-diglucuronide Embryophyta Marchantiaceae Marchantia polymorpha (Harborne and Baxter, 1999; Markham and Porter, 1974)
Luteolin 4′-neohesperidoside Asterids Apocynaceae Caralluma tuberculata (Brown et al., 1990)
Luteolin 3′,4′-diglucoside Liliopsida Orchidaceae Listera ovata (Williams, 1979)
Luteolin 3′,4′-diglucuronide Embryophyta Ophioglossaceae Lunularia cruciata (Harborne and Baxter, 1999; Markham and  Porter, 1974)
Luteolin 3′,4′-digalacturonide Embryophyta Marchantiaceae Marchantia berteroana (Harborne and Baxter, 1999; Markham and Porter, 1974)
Luteolin 7-(3”’-acetylapiosyl-(1->2)-xyloside) Asterids Campanulaceae or Lobeliaceae Campanula patula (Harborne and Baxter, 1999)
Luteolin 7-sulfate-3′-rutinoside Liliopsida Arecaceae Opsiandra maya (Harborne and Baxter, 1999)
Luteolin 3′-methyl ether 7-apiosyl-(1->2)-glucoside Rosids, Asterids Apiaceae, Fabaceae Apium graveolens, Dalbergiamonetarya (Harborne and Baxter, 1999)


Table 2: Luteolin content (mg/100g) in different sources

Food  Source Luteolin Contents Food  Source Luteolin Contents





Raw cauliflower


Raw Chinese Celery


Raw red cabbage


Dried spices, parsley

19.75 mg

Raw lettuce iceberg


Dried Parsley


Raw cabbage Chinese


Peppermint fresh


Raw Cabbage


Raw green peppers (hot chili)





Raw pepper Serrano


Juniper Berries


Raw peppers, jalapeno


Thyme, fresh


Raw Celery


Fresh Mexican Oregano


Raw Kohlrabi



Fresh sage


Raw Parsley


Fresh Rosemary


Raw Spinach


Raw Chives


Raw green sweet peppers


Raw Dishcloth Gourd


Raw red sweet peppers


            Fruits Raw Lemons without peel


Raw Beets


Raw Sweet potato leaves


Raw Brussels sprouts




How to cite this article
Manzoor, M. F., Ahmad, N., Manzoor, A., & Kalsoom, A. (2017). Food based phytochemical luteolin their derivatives, sources and medicinal benefits. Int. J. Agr.Life. Sci, 3(2), 195-207. doi: 10.22573/spg.ijals.017.s12200084.
“The authors declare no conflict of interest”.
© 2017 by the authors; licensee SKY FOX Publishing Group, Tamilnadu, India. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (